FDA Approves Type 2 Diabetes treatment
FDA has approved Glyxambi (empagliflozin and linagliptin) to improve blood sugar levels patients with type 2 diabetes. The once-daily tablet will fight diabetes in two ways: by forcing excess blood sugar out through the urine, and by spurring hormones in the body to produce more insulin and less glucose, or sugar.
Sanofi Introduces First Inhalable Insulin To US Market.
Sanofi introduced its inhalable insulin Afrezza (insulin human [rDNA origin]) in the US market. Afrezza, a rival to Pfizer’s Exubera, will be the only inhalable insulin drug available in the US, and promises faster delivery and better convenience than traditional injectable insulin treatments.
Statin Therapy and Risk of Fracture
Ad hoc analyis of the JUPITER Trial found 431 incident fractures reported and confirmed during the Jupiter study. Among participants allocated to rosuvastatin, 221 fractures were confirmed, compared with 210 among those allocated to placebo, such that the incidence of fracture in the rosuvastatin and placebo groups was 1.20 and 1.14 per 100 person-years, respectively (adjusted HR, 1.06 [95% CI, 0.88-1.28]; P=0.53).
Fruit Fly Study Identifies Insulin-Decreasing Decretin Hormone.
In a study in Cell Metabolism researchers identified a long sought insulin-decreasing decretin hormone in fruit flies and a related protein in human pancreatic beta cells. The discovery could have significant implications for the understanding of metabolism and the treatment of diabetes. The new hormone, named limostatin – after the Greek goddess of starvation, Limos – was found to decrease circulating insulin levels in fruit flies in response to fasting.
The Human Epigenome
More than 200 scientists working on an ambitious federal project have begun to understand the complicated system of switches that regulates genes, turning some on and others off, making. Their findings are published in 24 papers in Nature and other journals from Nature Publishing, with the most complete mapping of the human epigenome to date
להמשך קריאה ב-nature
FDA Approves New Thyroid Cancer Treatment
FDA has approved Lenvima (lenvatinib), following the publication of the 392-patient phase 3 SELECT trial. Lenvima halted the growth of thyroid cancer for 18.3 months, compared with 3.6 months in patients receiving a placebo and shrank tumors in 65 percent of patients. FDA warned on side effects including cardiac failure, thrombosis, liver damage, kidney damage, GI perforation or fistula, QT interval prolongation, hypocalcemia, headache, confusion, seizures, visual changes, hemorrhage, fetal risks, and impaired suppression of thyroid-stimulating hormone release.
Oral Treatment For Acromegaly Showed Significant Disease Control In Adults.
A research in JCEM indicated an oral treatment for acromegaly showed significant disease control in a phase III trial of adults. This drug – a new formulation of the peptide somatostatin analog known as octreotide – achieved reductions in GH and IGF1 for 65% of patients.